AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Tubulin alpha-1B chain

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P68363

UPID:

TBA1B_HUMAN

Alternative names:

Alpha-tubulin ubiquitous; Tubulin K-alpha-1; Tubulin alpha-ubiquitous chain

Alternative UPACC:

P68363; P04687; P05209; Q27I68; Q8WU19

Background:

Tubulin alpha-1B chain, also known as Alpha-tubulin ubiquitous, Tubulin K-alpha-1, and Tubulin alpha-ubiquitous chain, plays a pivotal role in cell structure and function. It is the major constituent of microtubules, essential for cell division, intracellular transport, and the maintenance of cell shape. Microtubules, composed of alpha- and beta-tubulin heterodimers, dynamically grow by adding GTP-tubulin dimers, facilitated by the GTPase activity of alpha-tubulin.

Therapeutic significance:

Understanding the role of Tubulin alpha-1B chain could open doors to potential therapeutic strategies. Its critical function in cell division and transport makes it a potential target for cancer therapy, as disrupting microtubule dynamics can inhibit cancer cell proliferation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.